EGFR and non-small cell lung carcinoma: Osimertinib (3, Scheme 1)13 is a third-generation EGFR inhibitor approved for patients affected by metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after the therapy with first- and second-generation EGFR inhibitors.14